AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic

$ETON

Eton Pharmaceuticals, Inc.

Price · $ETONvia TradingView
AI sentiment · 7d3 articles
AUG 2net (bullish − bearish)AUG 8
Bullish
2
Neutral
1
Bearish
0
Insider · 30dFeed →
Buys
—
0 txs
Sells
$1.1M
2 txs
Opaleye Management Inc.2× · $1.1M
10b5-1 plan0%
Top stories · $ETONMore →
AUG 7·rttnews.comMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

AUG 5·SEC EDGAR 8-K

Eton Pharmaceuticals, Inc. (ETON): Completion of Acquisition or Disposition of Assets

Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. eton20260803_8k.htm false 0001710340 0001710340 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2026 Date of Report (Date of earli

AUG 4·SEC EDGAR 8-K

Eton Pharmaceuticals, Inc. (ETON): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. eton20260731_8k.htm false 0001710340 0001710340 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2026 Date of Report (Date of earli

ETON sentiment & insider activity

Over the past 7 days, alphai's AI scored 3 news stories mentioning ETON (Eton Pharmaceuticals, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.

Recent ETON coverage spans insider activity, financial news and corporate actions.

In the last 30 days, ETON insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.1M). The most active reporter was Opaleye Management Inc. with 2 filings.

What's driving ETON

  • Licensing rights plus an NDA timeline can be a positive catalyst for pipeline value, but execution risk remains.

    rttnews.com · Aug 7, 2026

  • The filing adds a concrete commercialization pathway and cash-flow structure (upfront plus milestones and tiered royalties) tied to FDA approval and sales thresholds.

    SEC EDGAR 8-K · Aug 5, 2026

  • The 8-K is a corporate leadership change with disclosed compensation, likely modest near-term impact but relevant for governance and execution expectations.

    SEC EDGAR 8-K · Aug 4, 2026

  • The breakout is linked to improving fundamentals (profitability and sales growth) rather than only trial headlines.

    rttnews.com · Jul 24, 2026

  • The stock’s breakout is presented as momentum around rare-disease product progress, but the article does not disclose a new approval or earnings print on Tuesday.

    rttnews.com · Jul 22, 2026

alphai scores every news story that mentions ETON with an AI model for sentiment and relevance, and aggregates insider trades from Eton Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ETON

Score
AUG 7$MRNAMedrttnews.com

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

7 min read
AUG 5$ETONMedSEC EDGAR 8-K

Eton Pharmaceuticals, Inc. (ETON): Completion of Acquisition or Disposition of Assets

Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. eton20260803_8k.htm false 0001710340 0001710340 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2026 Date of Report (Date of earli

4 min read
AUG 4$ETONLowSEC EDGAR 8-K

Eton Pharmaceuticals, Inc. (ETON): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. eton20260731_8k.htm false 0001710340 0001710340 2026-07-31 2026-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2026 Date of Report (Date of earli

2 min read
JUL 17$AAPLMedyahoo.com

Apple upgraded, Brinker initiated: Wall Street's top analyst calls

Wall Street analysts issued multiple rating changes. HSBC upgraded Apple (AAPL) to Buy, lifting its target to $366 from $260, citing an operational turning point and an AI-driven product pipeline. JPMorgan upgraded 3M (MMM) to Overweight, target $180. Other actions included upgrades for AST SpaceMobile (ASTS), Ecolab (ECL), EchoStar (ECHO), and Brinker (EAT), plus downgrades for Oneok (OKE) and others.

2 min read
JUN 9$ETONLowSEC EDGAR 8-K

Eton Pharmaceuticals, Inc. (ETON): Submission of Matters to a Vote of Security Holders

Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. eton20260409_8k.htm false 0001710340 0001710340 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2026 Date of Report (Date of earlie

2 min read

Related tickers

More in Drug Manufacturers - Specialty & Generic